ASCO Annual Meeting: Gastrointestinal Cancer | Conference

Frontline Regorafenib Plus Pembrolizumab Reveals Antitumor Activity in HCC
June 10, 2021

Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.

Toripalimab and HAIC Plus Lenvatinib Produced Durable Responses in Advanced HCC
June 09, 2021

Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.

Liposomal Irinotecan Plus 5-FU/LV Improves Survival Outcomes in Biliary Tract Cancer
June 06, 2021

Liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU/LV) mproved progression-free survival (PFS) and overall survival (OS) in patients with metastatic biliary tract cancer whose disease had progressed after frontline gemcitabine/cisplatin.